



Editorials in this issue
Cite this article: Moncrieff J (2019). Persistent
adverse effects of antidepressants.
Epidemiology and Psychiatric Sciences 1–2.
https://doi.org/10.1017/S2045796019000520
Received: 18 August 2019
Accepted: 31 August 2019
Key words:
Adverse effects; antidepressants; drug side





© The Author(s) 2019. This is an Open Access
article, distributed under the terms of the
Creative Commons Attribution licence (http://
creativecommons.org/licenses/by/4.0/), which
permits unrestricted re-use, distribution, and
reproduction in any medium, provided the
original work is properly cited.
Persistent adverse effects of antidepressants
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Antidepressants have been prescribed to millions of people worldwide on the unproven
assumption that depression is caused or mediated by specific abnormalities of brain chemicals
that antidepressants can correct, alongside evidence of marginal differences from placebo on
depression rating scales in randomised trials. Yet, antidepressants are chemicals which alter
the normal functioning of the brain and other parts of the body in ways we do not fully under-
stand. It is becoming clear that far from normalising brain function, antidepressants disrupt
normal biological processes with potentially devastating consequences for some people who
take them.
We are not clear about the nature of the neurochemical and physiological changes that
occur immediately after taking an antidepressant, nor how they vary across the different
agents. We are even less certain about how the body, including the brain, adapts to the long-
term presence of these drugs, and we do not know whether the alterations produced by the
drugs return to normal once the drug is stopped, or whether they persist. Yet we know that
other drugs used for mental health problems sometimes cause irreversible brain alterations,
such as tardive dyskinesia caused by antipsychotics. The brain is a delicate organ; it may
not take much to permanently re-set its structure or function.
Historically, the medical community has been slow to appreciate the extent to which drugs
can interfere with normal brain and body functions. It took psychiatrists a long time to
acknowledge that tardive dyskinesia was caused by antipsychotics (Moncrieff, 2013). It has
taken three decades for the withdrawal effects of antidepressants to receive serious attention.
The prescription opioid epidemic in the United States continues despite mounting evidence
that the drugs can exacerbate chronic pain rather than relieve it (Velayudhan et al., 2014).
Two editorials in this issue demonstrate how ‘legacy effects,’ that is effects that occur or persist
after treatment ceases, seem to be a particular blind spot for both clinicians and researchers.
Withdrawal effects
Withdrawal effects are, in themselves, an indication that the body has been altered by the inges-
tion of a drug. We associate withdrawal effects with long-term use, but in fact, the body can
change, temporarily, even after a single dose of a drug. Animal studies show that one acute treat-
ment with an opiate provokes a period of heightened sensitivity to pain (hyperalgesia), which fol-
lows after the direct analgesic effect of the drug and lasts for a few days (Celerier et al., 2000).
Similarly, taking benzodiazepine hypnotics for just one or two days improves sleep initially, at
least slightly, but when the pill is stopped, people find it even more difficult to sleep than they
did before they took it (Soldatos et al., 1999). This situation is sometimes referred to as ‘rebound;’
a name for the compensatory-type effects that occur after the acute effects of a drug haveworn off.
Following long-term use, some drugs give rise to more severe and longer-lasting withdrawal
syndromes. Some are predictable ‘rebound’ type reactions (such as anxiety following benzodi-
azepine withdrawal), others, like tardive dyskinesia, are less predictable. Protracted withdrawal
following benzodiazepine cessation was recognised back in 1991 with symptoms including
anxiety, tinnitus and paraesthesia that lasted for many months and sometimes years. In
most, though not all, instances there was a gradual improvement over time, but symptoms per-
sisted in some cases, even despite the resumption of benzodiazepines (Ashton, 1991). Drugs
like alcohol and opiates seem less likely to cause protracted withdrawal, but the hypersensitiv-
ity to pain that is a recognised feature of opiate withdrawal can take up to five months to nor-
malise following detoxification (Treister et al., 2012).
Evidence on antidepressant withdrawal suggests a picture similar to the benzodiazepines.
There is a range of intensity and duration, with not everyone experiencing debilitating or
even noticeable symptoms, but there are numerous reports of withdrawal symptoms being
severe and protracted. As Hengartner, Davies & Read conclude, withdrawal reactions associated
with antidepressants are common, frequently severe and last from a few weeks to months and
sometimes even longer (Antidepressant withdrawal, the tide is finally turning).
Post-SSRI sexual dysfunction
Further evidence of lasting changes associated with antidepressants comes from the emerging
literature on post-selective serotonin reuptake inhibitor (SSRI)-sexual dysfunction. SSRIs are
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well-known to impair sexual function while they are being taken,
and Healy describes the accumulating evidence that difficulties
can persist following cessation of the drugs for months and some-
times years ( post-SSRI sexual dysfunction and other enduring
sexual dysfunctions). Persistent sexual impairment is also demon-
strated in male rats treated with SSRIs during adolescence (de
Jong et al., 2006; Simonsen et al., 2016) and Healy documents
how similar syndromes have been described following discontinu-
ation of certain other drugs such as finasteride (prescribed for
hair loss) and retinoids used for acne. It is difficult to estimate
the prevalence of post-SSRI persistent sexual dysfunction given
the currently limited data, but one survey identified that 34% of
respondents showed evidence of possibly having the condition,
and 4.3% showed a high probability of having it (Ben-Sheetrit
et al., 2015). The fact that it is consistent with acute effects of
SSRIs and with animal research supports the position that
post-SSRI-sexual dysfunction is a genuine consequence of SSRI
use rather than the re-emergence of symptoms of an underlying
depression, as sometimes suggested. Like prolonged antidepres-
sant withdrawal symptoms, Healy suggests that the usual course
is for post-SSRI-sexual dysfunction to improve gradually,
although possibly not in everyone.
Implications
There is a large-scale failure to appreciate the risks involved in
taking drugs that alter brain function on a long-term basis.
Some of these risks are foreseeable, some less so. Given the history
of benzodiazepines, we should have been able to anticipate that
SSRIs and other new drugs for depression and anxiety would pro-
duce withdrawal syndromes, although once again we were taken
unawares, and there seems to have been no research into this pos-
sibility before the drugs were launched. Syndromes like tardive
dyskinesia, or opioid-induced hyperalgesia, should remind us,
however, that the effects of drugs can be unexpected. The persist-
ence of harmful effects also suggests that in some cases drugs can
cause long-lasting changes.
The lack of systematic and well-funded research means that the
prevalence of antidepressant withdrawal and post-SSRI sexual
dysfunction remains uncertain, and the mechanisms obscure. It
is estimated that around 13% of the population of England are
taking antidepressants currently (Department of Health and
Social Care (DHSC), 2018) and data from the United States
from 2011–2014, put the figure at 12% (Pratt et al., 2017).
If even a small proportion of these people experience protracted
withdrawal or post-SSRI-sexual dysfunction, they amount to
sizeable problems. The fact that it has taken single-minded and
dedicated campaigners, many of them antidepressant users them-
selves, to bring these effects to the attention of the scientific and
professional community must be received as a wake-up call.
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